Treatment Information

Back

Bladder Cancer treatment details. Chemotherapy.

Alexianer Hospital Maria Hilf GmbH, Krefeld, Germany.

Survival: monthsCountry:Germany
Toxiciy Grade:5City/State/Province:Krefeld
Treatments:ChemotherapyHospital:Alexianer Hospital Maria Hilf GmbH
Drugs:Journal:Link
Date:Mar 2014

Description:

Patients:
This phase 2 study involved advanced or metastatic urothelial cancer patients who were separated into two different treatment groups. Group A consisted of 49 patients with a median age of 67.3 years; 37 were males. Group B had 40 patients with a median age of 64.4 years; 29 were males.
Treatment:
Patients in group A received chemotherapy with gemcitabine and cisplatin.

Patients in group B were treated with the chemotherapy agents gemcitabine and cisplatin as well as the biologic sorafenib.

Toxicities:
There was one treatment-related death in group A due to pancytopenia (decreased number of blood cells). Grade 4 thrombocytopenia was also reported.

The most severe toxicity reported in group B was grade 4 thrombocytopenia. Grade 3 leucopenia and diarrhea were also reported.

Results:
The median overall survival rates for groups A and B were 10.4 and 11.2 months, respectively.

Support:
Some of the authors have received funding from various pharmaceutical companies.

Correspondence: Dr. Susanne Krege; email: [email protected]



Back